Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Corvus Pharmaceuticals, Inc. (CRVS) had Income from Continuous Operations of $-10.16M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-10.16M |
|
-- |
|
-- |
|
$10.57M |
|
$-10.57M |
|
$0.41M |
|
$-10.16M |
|
$-10.16M |
|
$-10.16M |
|
|
Income from Continuous Operations |
$-10.16M |
$-10.16M |
|
$-10.16M |
|
$-10.57M |
|
$-11.00M |
|
82.84M |
|
82.84M |
|
$-0.12 |
|
$-0.12 |
|
| Balance Sheet Financials | |
$66.94M |
|
$0.22M |
|
$13.53M |
|
$80.47M |
|
$8.07M |
|
-- |
|
$0.63M |
|
$8.71M |
|
$71.77M |
|
$71.77M |
|
$71.77M |
|
74.68M |
|
| Cash Flow Statement Financials | |
$-23.61M |
|
$-18.68M |
|
$36.41M |
|
$8.74M |
|
$2.87M |
|
$-5.87M |
|
$3.76M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.29 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-23.75M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.15% |
|
-14.15% |
|
-12.62% |
|
-14.15% |
|
$0.96 |
|
$-0.29 |
|
$-0.28 |
|